Brazil, Nigeria emerging as key export destinations for Indian pharmaceuticals

Key Highlights

• “These markets reflect rising healthcare access, expanding public procurement, and growing reliance on Indian generics, reinforcing India’s role as a preferred supplier to high growth demand intensive regions,” an official said.
• The country’s pharmaceutical exports rose by 6.5 per cent to USD 20.48 billion during April-November 2025-26.
• The data also showed that the US continues to be the single largest destination, accounting for over 31 per cent of exports in April-November 2025, while the overall growth profile highlights a broadening of demand across multiple geographies, strengthening the stability of India’s pharma export basket, the official added.
• Alongside the US, countries such as France, the Netherlands, Canada, Germany, and South Africa registered steady increase, collectively contributing to export expansion while maintaining stable shares.
• Notably, the Netherlands added over USD 58 million in exports, reflecting India’s strengthening integration into European pharmaceutical distribution networks.